{
    "ticker": "SLNO",
    "name": "Soleno Therapeutics, Inc.",
    "description": "Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for rare diseases, particularly those involving metabolic disorders. Founded in 2014, Soleno's lead product candidate, DCCR (diazoxide choline controlled-release), is designed to treat Prader-Willi syndrome (PWS), a complex genetic disorder characterized by insatiable hunger, obesity, and related complications. The company's innovative approach combines advanced drug formulation with a deep understanding of the underlying biology of metabolic disorders. Soleno is committed to addressing unmet medical needs in rare diseases through rigorous clinical research, aiming to improve the quality of life for patients and their families. The company actively collaborates with stakeholders, including healthcare professionals and patient advocacy groups, to ensure comprehensive support and education for those affected by these challenging conditions. With a dedicated team of scientists and industry experts, Soleno Therapeutics is poised to make significant contributions to the field of rare disease treatment, striving to bring hope to patients and their families.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "https://www.soleno therapeutics.com",
    "ceo": "Anish Bhatnagar",
    "social_media": {
        "twitter": "https://twitter.com/SolenoThera",
        "linkedin": "https://www.linkedin.com/company/soleno-therapeutics/"
    },
    "investor_relations": "https://www.soleno therapeutics.com/investors",
    "key_executives": [
        {
            "name": "Anish Bhatnagar",
            "position": "CEO"
        },
        {
            "name": "David L. S. J. Ma",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "DCCR"
            ]
        }
    ],
    "seo": {
        "meta_title": "Soleno Therapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Soleno Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for rare metabolic disorders like Prader-Willi syndrome.",
        "keywords": [
            "Soleno Therapeutics",
            "Biopharmaceutical",
            "Rare Diseases",
            "Prader-Willi Syndrome",
            "DCCR"
        ]
    },
    "faq": [
        {
            "question": "What does Soleno Therapeutics specialize in?",
            "answer": "Soleno Therapeutics specializes in developing novel therapies for rare diseases, particularly metabolic disorders."
        },
        {
            "question": "What is DCCR?",
            "answer": "DCCR is Soleno's lead product candidate designed to treat Prader-Willi syndrome."
        },
        {
            "question": "Where is Soleno Therapeutics headquartered?",
            "answer": "Soleno Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Soleno Therapeutics founded?",
            "answer": "Soleno Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "AVEO",
        "CRIS",
        "CBAY",
        "SNOW"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}